IP Library Granted Patent US 8,715,700
Granted Patent B2
US 8,715,700 · App. 11/490,896 · Granted May 6, 2014

Alpha hydroxy acid sustained release formulation

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,715,700
App. No.
11/490,896
Granted
May 6, 2014
Kind
B2
Abstract

An oil-in-water emulsion containing one or more alpha hydroxy acids in which the oil phase of the emulsion contains a high proportion of polar constituents. The emulsion, even at high concentrations of alpha hydroxy acid, is not irritating when applied to the skin.

Claims (38)

1. An oil-in-water emulsion comprising a contiguous external aqueous phase and droplets consisting of an internal oil phase suspended in the contiguous external phase, which emulsion comprises an alpha-hydroxy acid at a concentration of at least 8.0% w/w, wherein the oil phase of the emulsion comprises a polar emollient and an emulsifier, wherein at least 80% w/w of the constituents of the oil phase of the emulsion, based on the relative amounts of each constituent as used to formulate the emulsion, are polar.

2. The emulsion of claim 1 wherein at least 85% w/w of the constituents of the oil phase of the emulsion are polar.

3. The emulsion of claim 1 wherein at least 90% w/w of the constituents of the oil phase of the emulsion are polar.

4. The emulsion of claim 1 wherein at least 95% w/w of the constituents of the oil phase of the emulsion are polar.

5. The emulsion of claim 1 wherein the oil phase of the emulsion is free of constituents that are not polar.

6. The emulsion of claim 1 wherein the emulsifier is selected from the group consisting of cationic emulsifier, non-ionic emulsifier, and weak anionic emulsifier.

7. The emulsion of claim 1 which is free of strong anionic emulsifiers.

8. The emulsion of claim 1 wherein the concentration of the alpha-hydroxy acid is at least 10% w/w.

9. The emulsion of claim 1 wherein the concentration of the alpha-hydroxy acid is at least 12% w/w.

10. The emulsion of claim 1 which is free of mineral oil, petrolatum, and silicone oil.

11. The emulsion of claim 1 which has a relative concentration by weight of polar emollients to non-polar emollients of at least 4:1.

12. The emulsion of claim 1 which has a relative concentration by weight of polar emollients to non-polar emollients of at least 10:1.

13. The emulsion of claim 1 which is free of non-polar emollients.

14. The emulsion of claim 1 wherein the pH of the emulsion is within 1.0 pH units of the dissociation constant (pKa) of the alpha hydroxy acid.

15. The emulsion of claim 14 wherein the pH of the emulsion is within 0.5 pH units of the dissociation constant (pKa) of the alpha hydroxy acid.

16. The emulsion of claim 1 wherein the alpha hydroxy acid is glycolic acid.

17. The emulsion of claim 1 which is free of strontium.

18. A method for treating skin comprising topically applying to the skin of an individual in need thereof an oil-in-water emulsion containing an external aqueous phase and droplets consisting of an oil phase dispersed within the external aqueous phase, which emulsion comprises an alpha-hydroxy acid at a concentration of at least 8.0% w/w, wherein the oil phase of the emulsion comprises a polar emollient and an emulsifier, wherein at least 80% w/w of the constituents of the oil phase of the emulsion, based on the relative amounts of each constituent as used to formulate the emulsion, are polar.

19. The method of claim 18 wherein the emulsifier is cationic, non-ionic, or weakly anionic.

20. The method of claim 18 wherein the emulsion is free of strong anionic emulsifiers.

21. The method of claim 18 wherein at least 85% w/w of the constituents of the oil phase of the emulsion are polar.

22. The method of claim 18 wherein at least 90% w/w of the constituents of the oil phase of the emulsion are polar.

23. The method of claim 18 wherein at least 95% w/w of the constituents of the oil phase of the emulsion are polar.

24. The method of claim 18 wherein the oil phase of the emulsion is free of constituents that are not polar.

25. The method of claim 18 wherein the concentration of the alpha-hydroxy acid in the emulsion is at least 10% w/w.

26. The method of claim 18 wherein the concentration of the alpha-hydroxy acid in the emulsion is at least 12% w/w.

27. The method of claim 18 wherein the emulsion is free of mineral oil, petrolatum, and silicone oil.

28. The method of claim 18 wherein the emulsion is free of non-polar emollients.

29. The method of claim 18 wherein the pH of the emulsion is within 1.0 pH units of the dissociation constant (pKa) of the alpha hydroxy acid.

30. The method of claim 29 wherein the pH of the emulsion is within 0.5 pH units of the dissociation constant (pKa) of the alpha hydroxy acid.

31. The method of claim 18 wherein the alpha hydroxy acid is glycolic acid.

32. The emulsion of claim 1 wherein each of the constituents of the oil phase has a solubility parameter higher than 7.5.

33. The emulsion of claim 32 wherein each of the constituents of the oil phase has a solubility parameter of 8.0 or higher.

34. The emulsion of claim 33 wherein each of the constituents of the oil phase has a solubility parameter of 8.5 or higher.

35. An oil-in-water emulsion containing an external aqueous phase and an internal phase dispersed within the external aqueous phase, wherein the dispersed phase comprises an oil phase and does not comprise a distinct aqueous area within the oil phase, which emulsion comprises an alpha-hydroxy acid at a concentration of at least 8.0% w/w, wherein the oil phase of the emulsion comprises a polar emollient and an emulsifier, wherein at least 80% w/w of the constituents of the oil phase of the emulsion, based on the relative amounts of each constituent as used to formulate the emulsion, are polar.

36. An oil-in-water emulsion containing an aqueous phase and an oil phase wherein the aqueous phase is continuous and the oil phase is dispersed within the continuous aqueous phase and wherein the emulsion does not contain a distinct aqueous phase dispersed within the continuous aqueous phase, which emulsion comprises an alpha-hydroxy acid at a concentration of at least 8.0% w/w, wherein the oil phase of the emulsion comprises a polar emollient and an emulsifier, wherein at least 80% w/w of the constituents of the oil phase of the emulsion, based on the relative amounts of each constituent as used to formulate the emulsion, are polar.

37. An oil-in-water emulsion containing a continuous phase and a dispersed phase within the continuous phase, wherein the continuous phase is an aqueous phase and wherein the dispersed phase consists of an oil phase, which emulsion comprises an alpha-hydroxy acid at a concentration of at least 8.0% w/w, wherein the oil phase of the emulsion comprises a polar emollient and an emulsifier, wherein at least 80% w/w of the constituents of the oil phase of the emulsion, based on the relative amounts of each constituent as used to formulate the emulsion, are polar.

38. An oil-in-water emulsion comprising an external aqueous phase and an internal oil phase dispersed within the external aqueous phase, which emulsion comprises an alpha-hydroxy acid at a concentration of at least 8.0% w/w, wherein the oil phase of the emulsion comprises a polar emollient and an emulsifier, wherein at least 80% w/w of the constituents of the oil phase of the emulsion, based on the relative amounts of each constituent as used to formulate the emulsion, are polar, and wherein the emulsion is not a multivesicular emulsion.

Assignments (22)
U.S. PATENT SECURITY AGREEMENT Recorded Nov 25, 2025
From: BAUSCH HEALTH IRELAND LIMITED
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 073715/0375 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
Reel/Frame 073637/0126 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMA POLAND SPOLKA Z ORGANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z.O.O.
Reel/Frame 073637/0222 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
Reel/Frame 073654/0300 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 073637/0001 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
SECURITY AGREEMENT (SECOND LIEN) Recorded Nov 4, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 062078/0276 →
SECURITY AGREEMENT (FIRST LIEN) Recorded Nov 4, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061882/0708 →
SECURITY AGREEMENT (SECOND LIEN) Recorded Oct 5, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061606/0468 →
SECURITY AGREEMENT (FIRST LIEN) Recorded Oct 4, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061595/0066 →
SECURITY INTEREST Recorded Jun 13, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON
Reel/Frame 060346/0705 →
SECURITY INTEREST Recorded Oct 5, 2021
From: BAUSCH & LOMB IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; DR. GERHARD MANN CHEM.-PHARM. FABRIK GMBH; TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 057821/0800 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 12, 2019
From: DOW PHARMACEUTICAL SCIENCES, INC.
To: BAUSCH HEALTH IRELAND LIMITED
Reel/Frame 050358/0528 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 3, 2019
From: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.À R.L.; VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z O. O.
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 049672/0652 →
SECURITY INTEREST Recorded Mar 11, 2019
From: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 048556/0758 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 045444/0634 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 045444/0299 →
NOTICE OF SUCCESSION OF AGENCY Recorded Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
SECURITY AGREEMENT Recorded Jul 18, 2011
From: VALEANT PHARMACEUTICALS INTERNATIONAL, A DELAWARE CORPORATION; ATON PHARMA, INC., A DELAWARE CORPORATION; CORIA LABORATORIES, LTD., A DELAWARE CORPORATION; DOW PHARMACEUTICAL SCIENCES, INC., A DELAWARE CORPORATION; VALEANT PHARMACEUTICALS NORTH AMERICA LLC, A DELAWARE LLC; PRESTWICK PHARMACEUTICALS, INC., A DELAWARE CORPORATION; VALEANT BIOMEDICALS, INC., A DELAWARE CORPORATION
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 026606/0061 →
PATENT SECURITY RELEASE AGREEMENT Recorded Mar 14, 2011
From: GOLDMAN SACHS LENDING PARTNERS LLC
To: VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS NORTH AMERICA; CORIA LABORATORIES, LTD.; DOW PHARMACEUTICAL SCIENCES, INC.; ATON PHARMA, INC.
Reel/Frame 025950/0048 →
SECURITY AGREEMENT Recorded Oct 4, 2010
From: ATON PHARMA, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA; VALEANT PHARMACEUTICALS INTERNATIONAL; CORIA LABORATORIES, LTD.; DOW PHARMACEUTICAL SCIENCES, INC.
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 025084/0169 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 15, 2006
From: CHANG, YUNIK; DESAI, NAYAN
To: DOW PHARMACEUTICAL SCIENCES
Reel/Frame 018270/0462 →